{"id":30892,"date":"2022-07-29T07:15:52","date_gmt":"2022-07-29T13:15:52","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=30892"},"modified":"2022-07-29T07:16:54","modified_gmt":"2022-07-29T13:16:54","slug":"brakke-viewpoint-july-29-2022","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/","title":{"rendered":"\u5e03\u62c9\u514b\u89c2\u70b9 2022 \u5e74 7 \u6708 29 \u65e5"},"content":{"rendered":"<p>\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u7684\u9ad8\u989d\u52a8\u7269\u836f\u7269\u4f7f\u7528\u8005\u8d39\u7528\u662f\u5426\u4f1a\u963b\u788d\u52a8\u7269\u836f\u7269\u7684\u521b\u65b0\uff1f<\/p>\n<p>\u6bcf\u5e74\uff0cFDA ADUFA\/AGDUFA \u8d39\u7528\u90fd\u4f1a\u56e0\u901a\u8d27\u81a8\u80c0\u3001\u5de5\u4f5c\u91cf\u4ee5\u53ca\u524d\u4e00\u5e74\u6536\u6b3e\u8d85\u989d\u6216\u4e0d\u8db3\u800c\u53d1\u751f\u53d8\u5316\u3002\u4ece 10 \u6708\u5f00\u59cb\uff0c\u65b0\u52a8\u7269\u836f\u7269\u7533\u8bf7\u5c06\u9700\u8981 $659,364 \u5f20\u652f\u7968\uff0c\u8865\u5145\u7533\u8bf7\u5c06\u9700\u8981 $329,682 \u5f20\u652f\u7968\uff0c\u6bd4\u53bb\u5e74\u591a 13.5%\u3002\u4eff\u5236\u836f ANADA \u5728 2023 \u5e74\u5c06\u9700\u8981 $494,983 \u5f20\u652f\u7968\uff0c\u4f4e\u4e8e 2022 \u5e74\u7684 $548,628 \u5f20\uff0c\u8fd9\u4e3b\u8981\u662f\u7531\u4e8e 2021 \u5e74\u7684\u6536\u6b3e\u8d85\u989d\u3002\u8fd9\u662f\u4e00\u5927\u7b14\u94b1\uff0c\u5b83\u5fc5\u5b9a\u4f1a\u5f71\u54cd\u521b\u65b0\u3002<\/p>\n<p>\u5de5\u4f5c\u91cf\u8ba1\u7b97\u63d0\u4f9b\u4e86\u4e00\u4e9b\u6709\u5173\u521b\u65b0\u7684\u6709\u8da3\u4fe1\u606f\u3002\u8fc7\u53bb 5 \u5e74\uff08\u622a\u81f3 2022 \u5e74 5 \u6708\uff09\u63d0\u4ea4\u7684 NADA \u5e73\u5747\u6570\u91cf\u4e3a 12.8\uff0c\u4e0e\u622a\u81f3 2018 \u5e74 9 \u6708\u7684 5 \u5e74\u76f8\u6bd4\u4e0b\u964d\u4e86 22%\uff0c\u800c 2018 \u5e74 9 \u6708\u7684\u5e73\u5747\u7533\u8bf7\u6570\u91cf\u4e3a 16.4\u3002FDA \u9884\u8ba1 2023 \u5e74\u7684 NADA \u5c06\u8fbe\u5230 5.25\u3002\u5c06\u8fd9 5 \u5e74\u7684\u8865\u5145\u7533\u8bf7\u4e5f\u51cf\u5c11\u4e86 22%\uff0c\u7814\u7a76\u7814\u7a76\u63d0\u4ea4\u51cf\u5c11\u4e86 7%\uff0c\u5236\u9020\u8865\u5145\u7533\u8bf7\u589e\u52a0\u4e86 4%\uff0c\u7814\u7a76\u65b9\u6848\u63d0\u4ea4\u589e\u52a0\u4e86 1%\u3002\u6240\u6709\u8fd9\u4e9b\u5bfc\u81f4\u5de5\u4f5c\u91cf\u603b\u4f53\u51cf\u5c11 4.5%\uff0c\u8fd9\u5bf9\u521b\u65b0\u6765\u8bf4\u5e76\u4e0d\u662f\u597d\u4e8b\u3002<\/p>\n<p>\u7136\u800c\uff0c\u4eff\u5236\u836f\u52a8\u7269\u836f\u7684\u5de5\u4f5c\u91cf\u6b63\u5728\u6fc0\u589e\u2014\u2014\u589e\u52a0\u4e86 77%\u3002\u5728\u540c\u6837\u7684\u4e24\u4e2a 5 \u5e74\u671f\u95f4\uff0cANADA \u589e\u52a0\u4e86 12.5%\uff0827 \u6bd4 24\uff09\uff0c\u4eff\u5236\u836f\u7814\u7a76\u63d0\u4ea4\u589e\u52a0\u4e86 125%\uff0c\u4eff\u5236\u836f\u7814\u7a76\u65b9\u6848\u63d0\u4ea4\u4e3a 77%\uff0c\u5236\u9020\u8865\u5145\u589e\u52a0\u4e86 30%\u3002FDA \u4f30\u8ba1\uff0c\u5230 2023 \u5e74\uff0c\u5c06\u6709 11.6 \u4efd\u5168\u989d\u6536\u8d39 ANADA \u63d0\u4ea4\uff0c\u662f NADA \u63d0\u4ea4\u7684\u4e24\u500d\u3002<\/p>\n<p>\u56e0\u6b64\uff0c\u98ce\u9669\u8f83\u4f4e\u3001\u6210\u672c\u8f83\u4f4e\u7684\u4eff\u5236\u836f\u5f00\u53d1\u53d6\u4ee3\u4e86\u98ce\u9669\u8f83\u9ad8\u3001\u6210\u672c\u8f83\u9ad8\u7684\u65b0\u836f\u5f00\u53d1\u3002\u5982\u679c\u4ea7\u54c1\u88ab\u89c6\u4e3a\u521b\u65b0\u4ea7\u54c1\uff0c\u5219\u6709\u89c4\u5b9a\u514d\u9664\u6216\u964d\u4f4e\u8d39\u7528\uff0c\u800c\u8d39\u7528\u5c06\u6210\u4e3a\u5c06\u4ea7\u54c1\u63a8\u5411\u5e02\u573a\u7684\u91cd\u5927\u969c\u788d\u3002FDA \u5e76\u672a\u516c\u5e03\u5411 FDA \u63d0\u4ea4\u5e76\u514d\u9664\u8d39\u7528\u7684 NADA \u6570\u91cf\u2014\u2014\u6211\u4eec\u8ba4\u4e3a\u8fd9\u4e2a\u6570\u5b57\u5fae\u4e0d\u8db3\u9053\u3002<\/p>\n<p>\u8fd9\u662f ADUFA IV \u7684\u6700\u540e\u4e00\u5e74\uff0c\u76ee\u524d\u6b63\u5728\u5c31 ADUFA V \u8fdb\u884c\u8c08\u5224\uff0c\u8be5\u6cd5\u6848\u5c06\u4e8e 2024 \u8d22\u5e74\u5f00\u59cb\u3002\u5e0c\u671b\u5b83\u7684\u7ed3\u6784\u80fd\u591f\u63a8\u52a8\u66f4\u591a\u521b\u65b0\u3002<\/p>\n<p><em>\u9c8d\u52c3\u00b7\u743c\u65af<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>FDA \u9ad8\u6602\u7684\u52a8\u7269\u836f\u54c1\u4f7f\u7528\u8005\u8d39\u7528\u662f\u5426\u4f1a\u963b\u788d\u52a8\u7269\u836f\u54c1\u7684\u521b\u65b0\uff1fFDA \u7684 ADUFA\/AGDUFA \u8d39\u7528\u6bcf\u5e74\u90fd\u4f1a\u56e0\u901a\u8d27\u81a8\u80c0\u3001\u5de5\u4f5c\u91cf\u4ee5\u53ca\u524d\u4e00\u5e74\u6536\u6b3e\u8fc7\u9ad8\u6216\u8fc7\u4f4e\u800c\u53d8\u5316\u3002\u4ece 10 \u6708\u5f00\u59cb\uff0c\u65b0\u7684\u52a8\u7269\u836f\u54c1\u7533\u8bf7\u5c06\u9700\u8981 $659,364 \u7684\u652f\u7968\uff0c\u8865\u5145\u7533\u8bf7\u5c06\u9700\u8981 $329,682 \u7684\u652f\u7968\uff0c\u6bd4\u53bb\u5e74\u589e\u52a0\u4e86 13.5%\u3002\u4eff\u5236\u836f ANADA \u5728 2023 \u5e74\u5c06\u9700\u8981 $494,983 \u7684\u652f\u7968\uff0c\u4f4e\u4e8e 2022 \u5e74\u7684 $548,628\uff0c\u4e3b\u8981\u539f\u56e0\u662f 2021 \u5e74\u7684\u6536\u6b3e\u8fc7\u9ad8\u3002\u8fd9\u7b14\u94b1\u6570\u989d\u5de8\u5927\uff0c\u5fc5\u7136\u4f1a\u5f71\u54cd\u521b\u65b0\u3002\u5de5\u4f5c\u91cf\u8ba1\u7b97\u4e2d\u6709\u4e00\u4e9b\u5173\u4e8e\u521b\u65b0\u7684\u6709\u8da3\u4fe1\u606f\u3002\u8fc7\u53bb\u4e94\u5e74\uff08\u622a\u81f32022\u5e745\u6708\uff09\u63d0\u4ea4\u7684NADA\u5e73\u5747\u6570\u91cf\u4e3a12.8\u4ef6\uff0c\u4e0e\u622a\u81f32018\u5e749\u6708\u7684\u4e94\u5e74\uff08\u5e73\u574716.4\u4ef6\uff09\u76f8\u6bd4\u51cf\u5c11\u4e8622%\u3002FDA\u9884\u8ba12023\u5e74\u5c06\u67095.25\u4ef6NADA\u3002\u5c06\u8fd9\u4e94\u5e74\u8fdb\u884c\u6bd4\u8f83\uff0c\u8865\u5145\u7533\u8bf7\u4e5f\u51cf\u5c11\u4e8622%\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u63d0\u4ea4\u51cf\u5c11\u4e867%\uff0c\u751f\u4ea7\u8865\u5145\u7533\u8bf7\u589e\u52a0\u4e864%\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u65b9\u6848\u63d0\u4ea4\u589e\u52a0\u4e861%\u3002\u6240\u6709\u8fd9\u4e9b\u5bfc\u81f4\u5de5\u4f5c\u91cf\u603b\u4f53\u51cf\u5c11\u4e864.5%\uff0c\u8fd9\u5bf9\u521b\u65b0\u6765\u8bf4\u5e76\u975e\u597d\u4e8b\u3002\u7136\u800c\uff0c\u4eff\u5236\u52a8\u7269\u836f\u54c1\u7684\u5de5\u4f5c\u91cf\u5374\u6fc0\u589e\u2014\u2014\u589e\u52a0\u4e8677%\u3002\u5728\u8fd9\u4e24\u4e2a 5 \u5e74\u671f\u95f4\uff0cANADA \u4e0a\u6da8\u4e86 12.5%\uff0827 \u6bd4 24\uff09\uff0c\u901a\u7528\u7814\u7a76\u7814\u7a76\u63d0\u4ea4<\/p>\n<div class=\"view-full-post\"><a href=\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\" class=\"view-full-post-btn\">\u67e5\u770b\u5b8c\u6574\u6587\u7ae0<\/a><\/div>\n<p>;<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-30892","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"Do high FDA Animal Drug Users Fees slow innovation in animal drugs? Each year the FDA ADUFA\/AGDUFA fees change due to inflation, workload, and prior year excesses or shortfalls in collections.\u00a0 Starting in October, New Animal Drug Applications will require a $659,364 check and a supplemental application will need a $329,682 check, 13.5% more than last year.\u00a0 A generic drug ANADA will need a $494,983 check in 2023, down from $548,628 in 2022 due primarily to excess collections in 2021.\u00a0 That\u2019s a lot of money and it must impact innovation. Some interesting information on innovation comes from the workload calculation.\u00a0 The average number of NADAs submitted over the last 5 years (ending May 2022) is 12.8, which is down 22% compared to the 5 years ending September 2018, which had an average of 16.4 applications.\u00a0 The FDA expects 5.25 NADAs in 2023.\u00a0 Comparing these same 5-year periods to each other, supplemental applications are down 22% also, investigational study submissions are down 7%, manufacturing supplements are up 4% and investigational protocol submissions are up 1%.\u00a0 This all leads to an overall 4.5% reduction in workload, which doesn\u2019t reflect well on innovation. However, the workload for Generic Animal Drugs is booming \u2013 it\u2019s up 77%. Over these same two 5-year periods, ANADAs are up 12.5% (27 vs 24), generic investigational study submissionsView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-29T13:15:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-29T13:16:54+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint July 29, 2022\",\"datePublished\":\"2022-07-29T13:15:52+00:00\",\"dateModified\":\"2022-07-29T13:16:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\"},\"wordCount\":334,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\",\"url\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2022-07-29T13:15:52+00:00\",\"dateModified\":\"2022-07-29T13:16:54+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint July 29, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/zh\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u6765\u81ea Brakke Consulting \u7684\u65b0\u95fb","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/","og_locale":"zh_CN","og_type":"article","og_title":"News from Brakke Consulting","og_description":"Do high FDA Animal Drug Users Fees slow innovation in animal drugs? Each year the FDA ADUFA\/AGDUFA fees change due to inflation, workload, and prior year excesses or shortfalls in collections.\u00a0 Starting in October, New Animal Drug Applications will require a $659,364 check and a supplemental application will need a $329,682 check, 13.5% more than last year.\u00a0 A generic drug ANADA will need a $494,983 check in 2023, down from $548,628 in 2022 due primarily to excess collections in 2021.\u00a0 That\u2019s a lot of money and it must impact innovation. Some interesting information on innovation comes from the workload calculation.\u00a0 The average number of NADAs submitted over the last 5 years (ending May 2022) is 12.8, which is down 22% compared to the 5 years ending September 2018, which had an average of 16.4 applications.\u00a0 The FDA expects 5.25 NADAs in 2023.\u00a0 Comparing these same 5-year periods to each other, supplemental applications are down 22% also, investigational study submissions are down 7%, manufacturing supplements are up 4% and investigational protocol submissions are up 1%.\u00a0 This all leads to an overall 4.5% reduction in workload, which doesn\u2019t reflect well on innovation. However, the workload for Generic Animal Drugs is booming \u2013 it\u2019s up 77%. Over these same two 5-year periods, ANADAs are up 12.5% (27 vs 24), generic investigational study submissionsView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/","og_site_name":"Brakke Consulting Website","article_published_time":"2022-07-29T13:15:52+00:00","article_modified_time":"2022-07-29T13:16:54+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"Amanda McDavid","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"2 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint July 29, 2022","datePublished":"2022-07-29T13:15:52+00:00","dateModified":"2022-07-29T13:16:54+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/"},"wordCount":334,"articleSection":["Viewpoints"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/","url":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/","name":"\u6765\u81ea Brakke Consulting \u7684\u65b0\u95fb","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2022-07-29T13:15:52+00:00","dateModified":"2022-07-29T13:16:54+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-july-29-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint July 29, 2022"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Brakke\u54a8\u8be2\u7f51\u7ad9","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"\u963f\u66fc\u8fbe\u00b7\u9ea6\u514b\u6234\u7ef4","url":"https:\/\/brakkeconsulting.com\/zh\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/posts\/30892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/comments?post=30892"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/posts\/30892\/revisions"}],"predecessor-version":[{"id":30893,"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/posts\/30892\/revisions\/30893"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/media?parent=30892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/categories?post=30892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/zh\/wp-json\/wp\/v2\/tags?post=30892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}